Vinod Ravi, MD, MBA

The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Disclosure information not submitted.

Presentation(s):

• Paper 23 - A PHASE 1/2 TRIAL OF GEMCITABINE, DOCETAXEL, AND HYDROXYCHLOROQUINE IN ADVANCED METASTATIC OSTEOSARCOMA: FINAL RESULTS

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST

• Paper 82 - PHASE I/II STUDY OF THE TGF-BETA-TRAP ENHANCED ONCOLYTIC ADENOVIRUS, ADAPT-001, WITH AND WITHOUT AN IMMUNE CHECKPOINT INHIBITOR FOR SARCOMA PATIENTS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 99 - INCIDENCE OF GERMLINE GENETIC MUTATIONS IDENTIFIED ON STANDARD-OF-CARE GENOMIC SEQUENCING FOR ADVANCED SARCOMAS

  Saturday, November 16, 2024
  2:00 PM – 3:00 PM PST

• Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST